Clinical Trial Update: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing R-DHAP versus POLA-R-DHAP followed by autologous transplant for relapsed or refractory diffuse large B-cell lymphoma was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CISPLATIN (cisplatin)
• CYTARABINE (CYTARABINE)
• DEXAMETHASONE (Dexamethasone)
• Rituximab (rituximab)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent | Phase 2 | Status: WITHDRAWN